To evaluate the feasibility of cotrimoxazole as an empirical prophylactic antibiotic for transrectal prostate biopsy (TRPB) in cases where standard pre-biopsy cultures yield inconclusive results, which may increase the risk of infectious complications.
Key Findings:
86% of patients received empiric prophylaxis with cotrimoxazole.
Infectious complications occurred within a defined follow-up period of 21 days, assessed based on specific criteria including fever, dysuria, and severe prostate pain.
Multiresistant bacteria were detected in 3% of patients via rectal swabs.
Interpretation:
Cotrimoxazole appears to be a feasible option for empirical prophylaxis in TRPB, particularly when standard pre-biopsy cultures are inconclusive, potentially addressing the gap left by restrictions on fluoroquinolones and fosfomycin.
Limitations:
Retrospective design may introduce bias.
Single-center study limits generalizability.
Potential confounding factors may affect the results.
Conclusion:
Cotrimoxazole can serve as an effective empirical antibiotic prophylaxis for TRPB, addressing the gap left by restrictions on fluoroquinolones and fosfomycin.
by Matthias Jahnen, Thomas Amiel, Florian Kirchoff, Jacob W. Büchler, Kathleen Herkommer, Kathrin Rothe, Valentin H. Meissner, Jürgen E. Gschwend, Lukas Lunger
